The global hepatitis diagnostic test market size was valued at USD 3.9 billion in 2016 and is expected to grow at a CAGR of 6.5% over the forecast period. Rising prevalence of hepatitis diagnostics is primarily driving the growth of the global market.
Data published by the World Health Organization (WHO) states that hepatitis is the main reason for liver cancer which accounts for approximately 80% of all the liver cancer cases reported worldwide and around 1.4 million deaths annually. Additionally, the report states that around 300 chronic cases are registered globally. Considering, high prevalence of the disease driving the demand for advanced diagnostic tools.
Increasing awareness regarding the disease and its symptoms is creating the demand for the detection of Hepatitis. In addition, constantly rising awareness regarding commercially available advanced products is fueling market growth.
The paradigm shift from conventional tools to molecular diagnosis has increased the efficiency of procedures and also has lowered the turnaround time. Molecular diagnostics involves genetic tests to confirm the exact strain of the causative virus. The nucleic acid assays used include HCV RNA and HBV DNA analysis tests. Hence, the availability of such advanced detection techniques is spurring the overall market growth.
The dominance of the blood tests segment is attributed to the large test volume as they are the 1st line detection tests for hepatitis diagnostics. However, imaging tests are performed as supportive detection tests for the confirmation of liver inflammation. Whereas, in chronic conditions, liver biopsies are performed in order to confirm the exact viral strain. Biopsies are also known to aid the detection of cancerous cells in liver post hepatitis infection.
Liver function tests are the first line detection for liver diseases which is expected to drive the growth of the segment significantly over the forecast period. Liver function tests are expected to dominate the blood tests market throughout the forecast period.
In addition, immunoassays are used to detect the presence of a specific virus in the sample with the help of antibodies and antigens. Furthermore, techniques such as RIBA, PCR system, ELISA, and CLIA are used to perform immunoassays that are not affordable to all patients across the globe.
North America dominated the market with the largest revenue share in 2016. Availability of advanced diagnostic tools and high awareness regarding these products are the key factors driving the growth of the market in North America.
The accelerated growth in the Canadian market can be attributed to the initiatives of the government and non-government organizations. For instance, The Public Health Agency of Canada organized the World Hepatitis Day in order to increase awareness regarding hepatitis detection. Thereby, leading to a demand surge for hepatitis detection in the country.
The global Hepatitis report by the WHO states that the prevalence of Type B of the disease in South East Asia is approximately 0.7%. It also states that the incidence rate of HCV infection in 1,000,000 people is 14.7. The WHO also states a few reasons such as unprotected sex, the vital spread of infections, and transfer for body fluids from infected individuals are expected to increase the burden of the disease in the Asia Pacific region. Consequently, the demand for detection techniques is anticipated to grow significantly in Asia Pacific in the near future.
The key players of the market include Siemens Ag, F. Hoffmann La-Roche, Abbott Laboratories; DiaSorin S.p.A; bioMeriuex, MedMira, Inc.; Hologic, Inc.; Danaher Corporation, and Bio-Rad Laboratories, etc. Strategies such as mergers and acquisitions, partnerships with small/local players are widely adopted by key players to sustain the competition.
Report Attribute |
Details |
Market size value in 2020 |
USD 5.0 billion |
Revenue forecast in 2025 |
USD 6.9 billion |
Growth Rate |
CAGR of 6.5% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD Billion and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Test type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; China; Japan; Brazil; Mexico; & South Africa |
Key companies profiled |
Siemens Healthineers; F. Hoffmann La-Roche; Abbott Laboratories; DiaSorin S.p.A; bioMeriuex; MedMira; Inc.; Hologic; Inc.; Danaher Corporation; Bio-Rad Laboratories. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the hepatitis diagnostics market report on the basis of test types and region:
Diagnostic Tests Outlook (Revenue, USD Million; 2014 - 2025)
Blood tests
Liver function tests
Immunoassays
Nucleic Acid Tests
Imaging Tests
Liver Biopsy
Regional Outlook (Revenue, USD Million; 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
China
Japan
Latin America
Mexico
Brazil
MEA
South Africa
b. The global hepatitis diagnostic test market size was estimated at USD 4.7 billion in 2019 and is expected to reach USD 5.0 billion in 2020.
b. The global hepatitis diagnostic test market is expected to grow at a compound annual growth rate of 6.5% from 2017 to 2025 to reach USD 6.9 billion by 2025.
b. North America dominated the hepatitis diagnostic test market with a share of 38.5% in 2019. This is attributable to availability of advanced diagnostic tools and high awareness regarding these products.
b. Some key players operating in the hepatitis diagnostic test market include Siemens Healthineers, F. Hoffmann La-Roche, Abbott Laboratories; DiaSorin S.p.A; bioMeriuex, MedMira, Inc.; Hologic, Inc.; Danaher Corporation, and Bio-Rad Laboratories.
b. Key factors that are driving the market growth include rising prevalence of hepatitis and increasing awareness regarding the disease & its symptoms, and constantly rising awareness regarding commercially available advanced products.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."